Records 1 - 30 (of 177 Records)
- Page last reviewed:Oct 1, 2023
- Page last updated:Dec 01, 2023
- Content source:
Records 1 - 30 (of 177 Records)
|Query Trace: Lung Neoplasms and meta-analysis and EGFR[original query]|
| Optimal Treatments for NSCLC Patients Harboring Primary or Acquired MET Amplification.
Technology in cancer research & treatment 2022 9 21 15330338221128414.
Sun Dantong, Tao Junyan, Yan Weihua, Zhu Jingjuan, Zhou Hai, Sheng Yingying, Xue Chaofan, Li Hong, Hou Hel
| Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomised controlled trials.
BMJ open 2022 8 12 (8): e062036.
Deng Wusheng, Wang Ke, Jiang Yun, Li Dingbin, Bao Chongxi, Luo Jing, Liu Liuyuan, Huang Bing, Kong Jinlia
| Efficacy and safety of EGFR inhibitors and radiotherapy in locally advanced non-small-cell lung cancer: a meta-analysis.
Future oncology (London, England) 2022 8 18 (27): 3055-3065.
Li Xue, Wang Fang, Jia Huijun, Lian Zhen, Ren Kai, Yuan Zhiyong, Wang Ping, Zhao Luj
| Efficacy of Osimertinib in EGFR-Mutated Advanced Non-small-Cell Lung Cancer With Different T790M Status Following Resistance to Prior EGFR-TKIs: A Systematic Review and Meta-analysis.
Frontiers in oncology 2022 12 863666.
Yi Xiao-Fang, Song Jun, Gao Ruo-Lin, Sun Li, Wu Zhi-Xuan, Zhang Shu-Ling, Huang Le-Tian, Ma Jie-Tao, Han Cheng-
| Computed tomography-guided lung biopsy for molecular tests: a meta-analysis.
Kardiochirurgia i torakochirurgia polska = Polish journal of cardio-thoracic surgery 2022 Jun 19 (2): 96-101.
Zhang Jian-Hua, Xia Feng-Fei, Yang Xiao-Shan, Li
| Prognostic value of soluble programmed cell death ligand-1 in patients with non-small-cell lung cancer: a meta-analysis.
Immunotherapy 2022 7 14 (12): 945-956.
Wang Yan, He Haiy
| Impact of Smoking Status in Combination Treatment with EGFR Tyrosine Kinase Inhibitors and Anti-Angiogenic Agents in Advanced Non-Small Cell Lung Cancer Harboring Susceptible EGFR Mutations: Systematic Review and Meta-Analysis.
Journal of clinical medicine 2022 Jun 11 (12): .
Lee Tai-Huang, Chen Hsiao-Ling, Chang Hsiu-Mei, Wu Chiou-Mei, Wu Kuan-Li, Kuo Chia-Yu, Wei Po-Ju, Chen Chin-Ling, Liu Hui-Lin, Hung Jen-Yu, Yang Chih-Jen, Chong Inn-W
| Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysis.
ESMO open 2022 Jun 7 (3): 100507.
Dafni U, Soo R A, Peters S, Tsourti Z, Zygoura P, Vervita K, Han J-Y, De Castro J, Coate L, Früh M, Hashemi S M S, Nadal E, Carcereny E, Sala M A, Bernabé R, Provencio M, Cuffe S, Roschitzki-Voser H, Ruepp B, Rosell R, Stahel R
| Adjuvant EGFR tyrosine kinase inhibitors for patients with resected EGFR-mutated non-small-cell lung cancer: a network meta-analysis.
Future oncology (London, England) 2022 6 18 (21): 2695-2707.
Tian Wentao, Tan Nuopei, Ke Jiawen, Zou Ji'an, Liu Xiaohan, Pan Yue, Zeng Yue, Peng Yurong, Wu Fa
| Concomitant Gastric Acid Suppressants on the Survival of Patients with Non-Small-Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Meta-Analysis.
International journal of clinical practice 2022 6 2022 3102641.
Xia Jun, Zhu Jiping, Li Lei, Xu Shiq
| Efficacy and safety of adjuvant EGFR-TKIs for resected non-small cell lung cancer: a systematic review and meta-analysis based on randomized control trials.
BMC cancer 2022 3 22 (1): 328.
Zhao Pengfei, Zhen Hongchao, Zhao Hong, Zhao Lei, Cao Bangw
| RT-based combination therapy for brain metastasis from NSCLC with non-EGFR mutation/ALK gene rearrangement: A network meta-analysis.
Frontiers in oncology 2022 12 12 1024833.
Wu Min, Jiang Jun, Zhang Xuewen, Chen Jie, Chang Qiaomei, Chen Ro
| A meta-analysis of adjuvant EGFR-TKIs for patients with EGFR mutation of resected non-small cell lung cancer.
Medicine 2022 12 101 (47): e31894.
Cui Ran, Wei Chun, Li Xianyi, Jiang
| EGFR Tyrosine Kinase Inhibitor Efficacy in Older Adult Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer: A Meta-Analysis and Systematic Review.
Medicina (Kaunas, Lithuania) 2022 11 58 (11): .
Chen Chang-Hung, Chou Deng-Wei, Chung Kuo-Mou, Chang Han-
| Efficacy and safety of osimertinib for patients with EGFR-mutated NSCLC: a systematic review and meta-analysis of randomized controlled studies.
Acta oncologica (Stockholm, Sweden) 2022 10 61 (11): 1347-1353.
Li Li, Huang Qin, Sun Jianhai, Yan Fei, Wei Wujie, Li Zihui, Liu Li, Deng J
| Concurrent TP53 mutations predict a poor prognosis of EGFR-mutant NSCLCs treated with TKIs: An updated systematic review and meta-analysis.
Oncology letters 2022 Nov 24 (5): 384.
Lan Bo, Zhao Na, Du Kang, Leng Baola
| First-line therapeutic strategy for patients with advanced non-small cell lung cancer with Leu858Arg epidermal growth factor receptor mutations: a Bayesian network meta-analysis.
Therapeutic advances in chronic disease 2022 10 13 20406223221125706.
Chen Chongxiang, Zhang Chunning, Lin Huaming, Liu Qianyin, Wu Limian, Zhou Chengzhi, Zhang Jiex
| Do patient characteristics affect EGFR tyrosine kinase inhibitor treatment outcomes? A network meta-analysis of real-world survival outcomes of East Asian patients with advanced non-small cell lung cancer treated with first-line EGFR-TKIs.
Thoracic cancer 2023 9 .
Huang-Chih Chang, Chin-Chou Wang, Chia-Cheng Tseng, Kuo-Tung Huang, Yu-Mu Chen, Yu-Ping Chang, Chien-Hao Lai, Wen-Feng Fang, Meng-Chih Lin, Hung-Yi Chua
| Survival outcomes of east Asian patients with advanced non-small cell lung cancer treated with first-line EGFR tyrosine kinase inhibitors: A network meta-analysis of real-world evidence.
Thoracic cancer 2023 9 .
Huang-Chih Chang, Kuo-Tung Huang, Chia-Cheng Tseng, Yu-Mu Chen, Chien-Hao Lai, Yu-Ping Chang, Yung-Che Chen, Hung-Yi Chuang, Chin-Chou Wa
| Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials.
European journal of medical research 2023 8 28 (1): 302.
Ruijian Li, Weiyi Li, Fang Zhang, Shanshan
| The efficacy and safety of immune checkpoint inhibitors for patients with EGFR-mutated non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy: A systematic review and network meta-analysis.
Cancer medicine 2023 8 .
Zhen Wang, Fang Zhou, Shan Xu, Kang Wang, Huan Di
| Efficacy and safety of EGFR-TKIs in combination with angiogenesis inhibitors as first-line therapy for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and meta-analysis.
BMC pulmonary medicine 2023 6 23 (1): 207.
Di Hu, Yan-Yan Zhou, Hong-Bo Ma, Miao-Miao Tao, Qun-Zhen Huang, Zhen-Zhou Yang, Qi Zh
| Infection with human cytomegalovirus, Epstein-Barr virus, and high-risk types 16 and 18 of human papillomavirus in EGFR-mutated lung adenocarcinoma.
Croatian medical journal 2023 5 64 (2): 84-92.
Suzana Harabajsa, Hajdi Šef?i?, Marija Klasi?, Marija Milavi?, Snježana Židovec Lepej, Ivana Grgi?, Matea Zajc Petranovi?, Marko Jakopovi?, Silvana Smojver-Ježek, Petra Kor
| Should We Perform Repeated Re-Biopsy for the Detection of T790M Mutation?
Cancer research and treatment 2023 4 .
Saerom Kim, Soo Han Kim, Jinmi Kim, Mi-Hyun Kim, Min Ki Lee, Jung Seop E
| Epidermal growth factor receptor inhibitors as adjuvant treatment for patients with resected non-small cell lung cancer harboring EGFR mutation: a meta-analysis of randomized controlled clinical trials.
World journal of surgical oncology 2023 2 21 (1): 45.
Zhao Ning, Wu Zhuo-Peng, Yang Jie, Feng Wei-Neng, Yang Sheng-Li, Luo Ying, Ye Jun, Wang Fei, Zhang Xiao-Wen, Xiao Ye, Wu Ling-Ling, Gu Wei-Qu
| Safety of Readministration of EGFR-TKI After Onset of Interstitial Lung Disease in Advanced EGFR-Mutated NSCLC: A Systematic Review and Meta-Analysis.
Clinical lung cancer 2023 11 .
Fumihiro Kashizaki, Hao Chen, Atsushi Miyasaka, Nanami Tsuchiya, Chihiro Yamada, Shunsuke Okazaki, Mai Kaneko, Taiki Kano, Yohei Kameda, Akitomo Kikuchi, Kentaro Yumoto, Hiroyuki Osawa, Harumi Koizumi, Kenichi Takahashi, Takeshi Kane
| Adjuvant therapy in completely resected, EGFR-mutant non-small cell lung cancer: a comparative analysis of treatment efficacy between EGFR-TKI and anti-PD-1/PD-L1 immunotherapy.
Journal for immunotherapy of cancer 2023 10 11 (10): .
Zichun Li, Xuanye Zhang, Yuhong Wang, Zhixin Yu, Chunlong Yang, Yixin Zhou, Shaodong Ho
| Efficacy and safety of antiangiogenic agents or chemotherapy plus EGFR-TKIs in advanced non-small cell lung cancer: A systematic review and network meta-analysis.
Thoracic cancer 2023 1 14 (6): 535-543.
Dai Jiali, Liu Xinyin, Li Jun, Qu Tianyu, Cui Yanan, Jin Shidai, Zhang Erbao, Guo Renh
| Comparison of gefitinib plus chemotherapy versus gefitinib alone for advanced non?small?cell lung cancer: A meta analysis.
Clinics (Sao Paulo, Brazil) 2023 1 78 100152.
Yi Min, He Ting, Wang Kaijin, Wei Yongga
| Side effects of tyrosine kinase inhibitors therapy in patients with non-small cell lung cancer and associations with EGFR polymorphisms: A systematic review and meta-analysis.
Oncology letters 2023 1 25 (2): 62.
Obradovic Jasmina, Todosijevic Jovana, Jurisic Vladim